US · ALVOW
Alvotech
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Luxembourg 102
- Website
- alvotech.com
Price · as of 2024-12-31
—
Market cap 119.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $112.78 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Alvotech's (ALVOW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALVOW | Alvotech | $0.40 | 119.82M | — | — | — | — | — | — | — | — | — | — | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | — | -1.22 | -68.51% | — | 0.00% | — | — | — | — | — |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| INDV | Indivior Pharmaceuticals … | $32.72 | 4.08B | +249% | +42% | -77% | -38% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| PRGO | Perrigo Company plc | $13.22 | 1.82B | -63% | -63% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
About Alvotech
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland.
- CEO
- Vilhelm Robert Wessman
- Employees
- 1.01K
- Beta
- 0.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).